Clinical Trial Update: Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 cost-effectiveness study evaluating PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• PEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: Ruijin Hospital | Conditions: Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor | Phase 4 | Status: UNKNOWN